05:06 AM EDT, 05/30/2025 (MT Newswires) -- Sanofi ( SNY ) and Regeneron Pharmaceuticals ( REGN ) said Friday that one of its phase 3 trials of itepekimab in adults who were former smokers with inadequately controlled chronic obstructive pulmonary disease, or COPD, met its primary endpoint while another did not meet the same primary endpoint.

The companies said phase 3 trial AERIFY-1 achieved the primary endpoint of reducing the annualized rate of acute moderate or severe COPD exacerbations and AERIFY-2 did not. itepekimab's safety profile was consistent with earlier trials, but its safety and efficacy remain under clinical investigation, the partners added.

Regeneron and Sanofi ( SNY ) said they continue to review the data and detailed results of the trials will be presented at a future medical meeting.